In Multiple Sclerosis (MS), CBD in preclinical models of MS resulted in a reduction of proinflammatory cytokines such as IL-17A, IFN-γ, TNF-α, IL-6 and IL-1b and an increase in anti-inflammatory cytokines such as IL-4, IL-10 and TGF-β. Here, TGFB1 is linked to myeloid sarcoma.